Scientific Congress Update: AHA 2007: New Developments in the Treatment of Acute Coronary Syndrome

Scientific Congress Update: AHA 2007: New Developments in the Treatment of Acute Coronary Syndrome

Please review the following information and click "continue" at the bottom of this screen to enter the activity.

Release Date: January 30, 2008
Expiration Date: January 29, 2009

Target Audience
This activity was developed to provide cardiologists, primary care physicians, emergency medicine physicians, and other healthcare professionals who care for and treat patients with ACS with the most up-to-date information being disseminated on therapeutic options for the management of ACS from patient stabilization following diagnosis to long-term prevention of repeat events.

Activity Overview
Acute coronary syndromes (ACS), a term used to describe conditions associated with myocardial ischemia, represents medical emergencies that frequently result in death within hours if not treated immediately and effectively. Current practice guidelines developed by the American College of Cardiology (ACC) and American Heart Association (AHA) outline treatment recommendations that emphasize the importance of pharmacologic therapy, principally anticoagulant and antiplatelet therapy, to modify the process and adverse consequences of ACS. Research continues to refine acute and long-term management strategies of ACS as new pharmacologic agents and scientific evidence become available.

The American Heart Association's annual Scientific Sessions is the preeminent meeting for discussion of new and evolving research in the area of cardiovascular disease and is the focus of this online CME activity. This activity, designed for physicians uanble to attend the meeting, provides an opportunity to view new information presented during Scientific Sessions and examine its potential impact on clinical practice and patient outcomes, while reinforcing current guidelines and best practices. The role of existing and emerging antiplatelet agents in the treatment of ACS will be emphasized.

1. American Heart Association. Heart disease and stroke statistics: 2007 update. http://www.heart.org/downloadable/heart/1166712318459HS_StatsInsideText.pdf.

Activity Outline:
Segment 1: Late-breaking Clinical Trials

Approx 30 minutes discussion
Video segments:
- Califf: TRITON
- Stone: MERLIN
- Saceudo: COURAGE
Panel discussion following each clip

Segment 2: Current Issues Impacting the Diagnosis and Treatment of ACS

Approx 30 minutes discussion
Video segments:
- Kontos: CT angiography
- Kontos Biomarkers
- Stone: Men vs. Women
Panel discussion following each clip

Educational Objectives
After completing this activity, the participant should be able to:

Accreditation Statement
Physicians
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for Physicians. Temple University School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)�.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing
This continuing nursing education activity was approved by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Registered nurses will receive up to 1.0 contact hours.

Studio Faculty
Alfred A. Bove, MD, PhD (Moderator)
Chairman, Section of Cardiology
Temple University School of Medicine

Mark I. Furman, MD, FACC, FAHA
Chief of Cardiovascular Medicine, South Shore Hospital
South Weymouth, MA
Member of the Cardiology Division, Brigham and Women's Hospital
Harvard Medical School, Boston, MA

Sidney C. Smith, Jr., MD, FACC, FAHA, FESC
Professor of Medicine
Director, Center for Cardiovascular Science and Medicine
University of North Carolina at Chapel Hill

Field Faculty
Robert Califf, MD
Vice Chancellor for Clinical Research
Duke University

Michael Kontos, MD
Assistant Professor of Cardiology
Virginia Commonwealth University

Jorge Saucedo, MD
Vice Chief, Cardiology
University of Oklahoma Health Sciences Center
Director, Cardiac Catheterization Laboratories
Associate Professor of Medicine

Peter Stone, MD
Director, Clinical Trials Center
Brigham & Women's Hospital
Co-Director, Coronary Care Unit
Brigham & Women's Hospital
Associate Professor of Medicine
Harvard Medical School

Disclosure Declaration
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Any medications or treatment methods suggested in this CE activity should not be used by the practitoner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Unlabeled Use Disclosure
This activity discusses late breaking clinical trials data presented at the American Heart Association 2007 Annual meeting. Some of the information presented may refer to products or devices that are not approved for use by the Food and Drug Administration (FDA).